{"disease":{"id":"donafenib","name":"donafenib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05200221","title":"A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05205629","title":"A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT06609876","title":"Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05262959","title":"A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}